305P Role of the pan-immune-inflammatory value in stage III NSCLC treated with chemoradiotherapy with or without durvalumab

rates), R0 resection rate, and the incidence of severe post-treatment adverse events (AEs).Results: A total of 60 patients were included.Fifty-eight (97%) received at least one preoperative dose of IOT, either alone or in combination with chemotherapy, whereas two patients declined the proposed treatment.Incomplete preoperative therapy was observed in 16% of patients, and surgery was omitted in 12%.An R0 resection was achieved in 90% of those who underwent resection.Grade 3 adverse events (AEs) occurred in 16% of patients.Among the seven patients in whom planned surgery was not performed, the reasons were disease progression (n=5), treatment-related toxicity (n=1), and patient choice (n=1).Conclusions: Attrition in NSCLC treatment protocols remains a critical issue, particularly in patients who are candidates for curative-intent surgery.Whenever feasible, minimizing protocol attrition through individualized management and close multidisciplinary coordination is essential to maximize the therapeutic benefit of immunotherapy in resectable NSCLC and ultimately improve patient outcomes.